Business Context and Reporting Period
This Form 8-K Current Report was filed by Anavex Life Sciences Corp. on December 21, 2007, covering events occurring on December 17, 2007. The company is incorporated in Nevada with principal executive offices in Geneva, Switzerland.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the appointment of Dr. Cameron Durrant to the Board of Directors, effective December 17, 2007. The updated Board of Directors now consists of:
- Harvey Lalach
- Dr. Panos Kontzalis
- Dr. Alexandre Vamvakides
- Dr. Cameron Durrant
Dr. Durrant brings significant industry experience, having previously served as President and CEO of Pediamed Pharmaceuticals and holding executive positions at Johnson & Johnson, Merck & Co., GlaxoSmithKline, and Pharmacia (now Pfizer).
Guidance, Outlook, and Risks
The filing does not contain financial guidance, forward-looking outlook statements, risk factors, contingencies, or unusual items. The document serves solely to disclose the director appointment under Item 5.02 and Regulation FD (Item 7.01).
Investor Verification Checklist
- Verify Dr. Cameron Durrant's current role and tenure at Anavex Life Sciences Corp.
- Confirm the full composition of the Board of Directors as of the filing date.
- Review the attached news release (Exhibit 99.1) for additional context on the appointment.
- Check subsequent filings for any financial updates, as this 8-K contains no financial data.